DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to ...

Carvykti outperforms competitors like Abecma, with potential expansion into earlier lines of multiple myeloma treatment, though risks like side effects remain. LEGN stock is undervalued given ...

They co-developed Abecma (idecabtagene vicleucel), a BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy for multiple myeloma, which secured US Food and Drug Administration (FDA ...

The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. “A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out ...

Princeton, N.J., biopharmaceutical company Bristol Myers and 2seventy are partners on the gene therapy Abecma, which is approved in the U.S. for adults with the blood cancer multiple myeloma.

Spun out of bluebird bio in 2021, 2seventy bio doubled-down on support for the commercial success of its partnered therapy with Bristol Myers Squibb, Abecma, idecabtagene vicleucel (ide-cel), in ...

Local government crews in Washington began on Monday morning to remove the Black Lives Matter mural that was painted near the White House nearly five years ago. Errin Haines discusses.March 11, 2025 ...

"A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all ...